RMI2
Basic information
Region (hg38): 16:11249619-11381662
Previous symbols: [ "C16orf75" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (2 variants)
- Autoimmune hemolytic anemia;Autoimmune thrombocytopenia (2 variants)
- Autoinflammatory syndrome with immunodeficiency (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the RMI2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 18 | 18 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 81 | 17 | 111 | |||
Total | 2 | 3 | 99 | 8 | 17 |
Variants in RMI2
This is a list of pathogenic ClinVar variants found in the RMI2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-11254001-T-C | - | no classification for the single variant (-) | ||
16-11254849-C-G | not specified | Likely benign (Mar 01, 2023) | ||
16-11254862-G-A | not specified | Uncertain significance (Mar 20, 2024) | ||
16-11254875-C-T | Autoinflammatory syndrome with immunodeficiency | Uncertain significance (Dec 02, 2024) | ||
16-11254880-A-G | EBV-positive nodal T- and NK-cell lymphoma | Likely benign (-) | ||
16-11254882-G-A | Benign (Sep 01, 2022) | |||
16-11254902-G-A | Uncertain significance (Feb 10, 2022) | |||
16-11254909-G-C | not specified | Uncertain significance (Apr 28, 2022) | ||
16-11254915-G-A | Benign (Aug 10, 2018) | |||
16-11254919-C-T | Autoinflammatory syndrome with immunodeficiency | Likely pathogenic (Oct 04, 2023) | ||
16-11254961-G-A | not specified | Uncertain significance (Jun 27, 2022) | ||
16-11254968-C-T | not specified | Uncertain significance (Jun 28, 2022) | ||
16-11254991-C-G | not specified | Uncertain significance (Feb 28, 2023) | ||
16-11254997-A-G | not specified | Uncertain significance (Jun 07, 2024) | ||
16-11254998-T-TGCCGC | Autoinflammatory syndrome with immunodeficiency | Pathogenic (Jun 17, 2021) | ||
16-11254998-T-TGCGGC | Autoimmune hemolytic anemia;Autoimmune thrombocytopenia • Autoinflammatory syndrome with immunodeficiency | Pathogenic (Jul 01, 2021) | ||
16-11255013-C-A | not specified | Uncertain significance (Feb 17, 2024) | ||
16-11255016-C-G | not specified | Uncertain significance (Dec 28, 2023) | ||
16-11255016-C-T | Uncertain significance (Jul 19, 2022) | |||
16-11255017-G-T | Malignant lymphoma, large B-cell, diffuse • Neoplasm | Pathogenic (Dec 04, 2023) | ||
16-11255019-A-G | Systemic lupus erythematosus • AUTOINFLAMMATORY SYNDROME, FAMILIAL, WITHOUT IMMUNODEFICIENCY | Pathogenic/Likely pathogenic (Jun 17, 2021) | ||
16-11255025-C-A | Autoinflammatory syndrome with immunodeficiency | Likely pathogenic (Apr 04, 2024) | ||
16-11255040-G-A | not specified | Uncertain significance (Jan 10, 2023) | ||
16-11255046-C-G | Uncertain significance (Jan 01, 2023) | |||
16-11255055-C-G | not specified | Uncertain significance (Feb 15, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
RMI2 | protein_coding | protein_coding | ENST00000312499 | 2 | 102144 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0190 | 0.517 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.621 | 45 | 34.7 | 1.30 | 0.00000157 | 909 |
Missense in Polyphen | 14 | 13.838 | 1.0117 | 290 | ||
Synonymous | -1.49 | 19 | 12.3 | 1.54 | 5.85e-7 | 316 |
Loss of Function | -0.350 | 2 | 1.53 | 1.31 | 6.47e-8 | 41 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Essential component of the RMI complex, a complex that plays an important role in the processing of homologous recombination intermediates. It is required to regulate sister chromatid segregation and to limit DNA crossover. Essential for the stability, localization, and function of BLM, TOP3A, and complexes containing BLM. In the RMI complex, it is required to target BLM to chromatin and stress-induced nuclear foci and mitotic phosphorylation of BLM. {ECO:0000269|PubMed:18923082, ECO:0000269|PubMed:18923083, ECO:0000269|PubMed:27977684}.;
- Disease
- DISEASE: Note=A homozygous deletion of RMI2 has been found in a family with a Bloom-like syndrome and is probable responsible for the phenotype. Patients manifest depigmented skin lesions, multiple cafe-au-lait macules, and growth deficiency. Cells from affected individuals show a high rate of sister chromatid exchange and increased chromosomal breaks. {ECO:0000269|PubMed:27977684}.;
- Pathway
- Fanconi anemia pathway - Homo sapiens (human);HDR through Single Strand Annealing (SSA);HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA);DNA Repair;Gene expression (Transcription);DNA Double-Strand Break Repair;Generic Transcription Pathway;Homology Directed Repair;RNA Polymerase II Transcription;G2/M DNA damage checkpoint;G2/M Checkpoints;Cell Cycle Checkpoints;Regulation of TP53 Activity through Phosphorylation;Regulation of TP53 Activity;Transcriptional Regulation by TP53;Cell Cycle;Processing of DNA double-strand break ends;Presynaptic phase of homologous DNA pairing and strand exchange;Homologous DNA Pairing and Strand Exchange;Resolution of D-loop Structures through Holliday Junction Intermediates;Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA);Resolution of D-Loop Structures;HDR through Homologous Recombination (HRR)
(Consensus)
Recessive Scores
- pRec
- 0.114
Haploinsufficiency Scores
- pHI
- 0.402
- hipred
- Y
- hipred_score
- 0.807
- ghis
- 0.687
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.114
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Rmi2
- Phenotype
Gene ontology
- Biological process
- DNA replication;DNA repair;regulation of sister chromatid segregation;negative regulation of double-strand break repair via homologous recombination
- Cellular component
- nucleoplasm;cytosol;nuclear speck
- Molecular function
- DNA binding;protein binding